P506: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE CLEARANCE IS A STRONGER PREDICTOR OF PATIENT OUTCOME THAN TREATMENT INTENSITY IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA

• A. Bazinet,
• T. Kadia,
• N. Short,
• G. Borthakur,
• S. Wang,
• S. Loghavi,
• J. Jorgensen,
• K. Patel,
• C. DiNardo,
• N. Daver,
• Y. Alvarado,
• F. Haddad,
• S. Pierce,
• M. Andreeff,
• E. Jabbour,
• M. Konopleva,
• H. Kantarjian,
• F. Ravandi

Affiliations

A. Bazinet

1 Leukemia

T. Kadia

1 Leukemia

N. Short

1 Leukemia

G. Borthakur

1 Leukemia

S. Wang

2 Hematopathology, University of Texas MD Anderson Cancer Center, Houston, United States of America

S. Loghavi

2 Hematopathology, University of Texas MD Anderson Cancer Center, Houston, United States of America

J. Jorgensen

2 Hematopathology, University of Texas MD Anderson Cancer Center, Houston, United States of America

K. Patel

2 Hematopathology, University of Texas MD Anderson Cancer Center, Houston, United States of America

C. DiNardo

1 Leukemia

N. Daver

1 Leukemia

Y. Alvarado

1 Leukemia

F. Haddad

1 Leukemia

S. Pierce

1 Leukemia

M. Andreeff

1 Leukemia

E. Jabbour

1 Leukemia

M. Konopleva

1 Leukemia

H. Kantarjian

1 Leukemia

F. Ravandi

1 Leukemia